Asian cannabis company CannAcubed has announced a new supply deal with Hong Kong-based pharma company Sanai, with an undisclosed volume of pure pharmaceutical grade 99.9 percent CBD isolate delivered to the Sanai head office last week.
The two parties now plan to work in partnership on new product development and distribution of CBD related items into Hong Kong and the wider Asian market, with Sanai looking to become a leading manufacturer and supplier of CBD-based products.
Glenn Davies, Group CEO of CannAcubed, said, “This is a milestone achievement for us here in Asia. We worked very closely with the Sanai executive team to ensure the end product met every safety and regulartory standard for their group and the HK market around compliance. It’s just the beginning now, and this lays the foundation to move quickly on greater supply and other products for Sanai Health and the wider Hong Kong market.
Fred Cheng, Director Sanai Health Group, continued, “We had unique requirements and very strict guidelines on what could and what couldn’t be accepted into the HK market. The global CannAcubed team worked through the entire process with us with complete visibility and transparency and laid the ground work for a solid long-term partnership.”